Changes in protein and gene expression of angiotensin II receptors (AT1 and AT2) in aorta of diabetic and hypertensive rats


Por: Romero-Nava R., Rodriguez J.E., Reséndiz-Albor A.A., Sánchez-Munõz F., Ruiz-Hernandéz A., Huang F., Hong E., Villafanã S.

Publicada: 1 ene 2016
Resumen:
Diabetes and hypertension have been associated with cardiovascular diseases and stroke. Some reports have related the coexistence of hypertension and diabetes with increase in the risk of developing vascular complications. Recently some studies have shown results suggesting that in the early stages of diabetes and hypertension exist a reduced functional response to vasopressor agents like angiotensin II (Ang II), which plays an important role in blood pressure regulation mechanism through the activation of its AT1 and AT2 receptors. For that reason, the aim of this work was to study the gene and protein expression of AT1 and AT2 receptors in aorta of diabetic SHR and WKY rats. Diabetes was induced by the administration of streptozotocin (60 mg/kg i.p.). After 4 weeks of the onset of diabetes, the protein expression was obtained by western blot and the mRNA expression by RT-PCR. Our results showed that the hypertensive rats have a higher mRNA and protein expression of AT1 receptors than normotensive rats while the AT2 expression remained unchanged. On the other hand, the combination of diabetes and hypertension increased the mRNA and protein expression of AT1 and AT2 receptors significantly. In conclusion, our results suggest that diabetes with hypertension modifies the mRNA and protein expression of AT1 and AT2 receptors. However, the overexpression of AT2 could be associated with the reduction in the response to Ang II in the early stage of diabetes. © 2016 Taylor and Francis Group, LLC.

Filiaciones:
Romero-Nava R.:
 Sección de Posgrado, Instituto Politécnico Nacional, Av. Salvador Dýáz Mirón s/n, esq, Delegación-Miguel-Hidalgo, Mexico

Rodriguez J.E.:
 Sección de Posgrado, Instituto Politécnico Nacional, Av. Salvador Dýáz Mirón s/n, esq, Delegación-Miguel-Hidalgo, Mexico

Reséndiz-Albor A.A.:
 Sección de Posgrado, Instituto Politécnico Nacional, Av. Salvador Dýáz Mirón s/n, esq, Delegación-Miguel-Hidalgo, Mexico

Sánchez-Munõz F.:
 Departamento de Inmunologiá, Instituto Nacional de Cardiologiá Ignacio Chávez, México D.F., Mexico

Ruiz-Hernandéz A.:
 Sección de Posgrado, Instituto Politécnico Nacional, Av. Salvador Dýáz Mirón s/n, esq, Delegación-Miguel-Hidalgo, Mexico

Huang F.:
 Departamento de Farmacologiá y Toxicologiá, Hospital Infantil de México Federico Gómez (HIMFG), México D.F., Mexico

Hong E.:
 Departamento de Neurofarmacobiologiá, Centro de Investigación y de Estudios Avanzados, México D.F., Mexico

Villafanã S.:
 Sección de Posgrado, Instituto Politécnico Nacional, Av. Salvador Dýáz Mirón s/n, esq, Delegación-Miguel-Hidalgo, Mexico
ISSN: 10641963
Editorial
Informa Healthcare, TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND, Estados Unidos America
Tipo de documento: Article
Volumen: 38 Número: 1
Páginas: 56-62
WOS Id: 000367921300008
ID de PubMed: 26268856

MÉTRICAS